ReviewFrontiers in pharmacology2023
Dysregulated neuromodulation in the anterior cingulate cortex in chronic pain.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Biomarker use in predicting transcranial direct-current stimulation (tDCS) response: a systematic scoping review.Frontiers in psychiatry · 2026Pooled it
- Comprehensive Assessment of Druggable Targets in Cortical Neurons Reveals Biological Limits of Cell Type-Specific Neuropharmacology.Biomedicines · 2026Article
- Magnetic Resonance Imaging Monitoring of the Safety of Repeated Low-Intensity Focused Ultrasound Exposure at Three Brain Locations.Neuromodulation : journal of the International Neuromodulation Society · 2026Article
- Brain-immune correlates of quality of life in adolescents with chronic musculoskeletal pain.Brain, behavior, and immunity · 2026Article
- Altered brain-behavior coupling during inhibitory control in ankylosing spondylitis: ERP evidence from NoGo-P3 component.PloS one · 2026Article
- Synergistic deficits in parvalbumin interneurons and dopamine signaling drive ACC dysfunction in chronic pain.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Astrocytes in Rodent Anxiety-Related Behavior: Role of Calcium and Beyond.International journal of molecular sciences · 2025Review
- Noradrenergic Mechanisms and Circuitry of Hyperkatifeia in Alcohol Use Disorder.Biological psychiatry · 2025Review
- Targeting γ-aminobutyric acid pathways in irritable bowel syndrome: bridging central nervous system, enteric dysfunction, and the microbiota-gut-brain axis.Frontiers in pharmacology · 2025Review
- External trigeminal nerve stimulation for neuropsychiatric disorders: mechanisms, efficacy, and future directions.Frontiers in neurology · 2025Review
- The Locus Coeruleus in Chronic Pain.International journal of molecular sciences · 2024Review
- White matter differences in motor and affective-motivational networks of pain-indifferent carriers of the R221W mutation.Neurobiology of pain (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain is a significant global socioeconomic burden with limited long-term treatment options. The intractable nature of chronic pain stems from two primary factors: the multifaceted nature of pain itself and an insufficient understanding of the diverse physiological mechanisms that underlie its initiation and maintenance, in both the peripheral and central nervous systems. The development of novel non-opioidergic analgesic approaches is contingent on our ability to normalize the dysregulated nociceptive pathways involved in pathological pain processing. The anterior cingulate cortex (ACC) stands out due to its involvement in top-down modulation of pain perception, its abnormal activity in chronic pain conditions, and its contribution to cognitive functions frequently impaired in chronic pain states. Here, we review the roles of the monoamines dopamine (DA), norepinephrine (NE), serotonin (5-HT), and other neuromodulators in controlling the activity of the ACC and how chronic pain alters their signaling in ACC circuits to promote pathological hyperexcitability. Additionally, we discuss the potential of targeting these monoaminergic pathways as a therapeutic strategy for treating the cognitive and affective symptoms associated with chronic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.